Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease
There are nearly 50 million Alzheimer’s disease (AD) patients worldwide, 90% of whom develop behavioral and psychological symptoms of dementia (BPSD), which increase the mortality rate of patients, and impose an economic and care burden on families and society. As a neurotransmitter and neuromodulat...
Saved in:
| Main Authors: | Hui-Hua Li, Xiao-Yan Yao, Sheng Tao, Xue Sun, Pan-pan Li, Xi-xin Li, Zhu-Li Liu, Chao Ren |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Behavioural Neurology |
| Online Access: | http://dx.doi.org/10.1155/2021/5533827 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
409 Assessing the preclinical potential of the antidepressant agomelatine for Alzheimer’s disease
by: Grace Terry, et al.
Published: (2025-04-01) -
Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndrome
by: Melissa R. Jenkins, et al.
Published: (2025-04-01) -
Agomelatine: A review for general practitioners
by: K. Outhoff
Published: (2012-06-01) -
Protein-protein interactions underlying the behavioral and psychological symptoms of dementia (BPSD) and Alzheimer's disease.
by: Yimin Mao, et al.
Published: (2020-01-01) -
Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease
by: Kalina Ilieva, et al.
Published: (2020-12-01)